Cargando…

Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway

Non-alcoholic fatty liver disease (NAFLD) and -steatohepatitis (NASH) imply a state of excessive fat built-up in livers with/or without inflammation and have led to serious medical concerns in recent years. Antrodan (Ant), a purified β-glucan from A. cinnamomea has been shown to exhibit tremendous b...

Descripción completa

Detalles Bibliográficos
Autores principales: Chyau, Charng-Cherng, Wang, Hsueh-Fang, Zhang, Wen-Juan, Chen, Chin-Chu, Huang, Shiau-Huei, Chang, Chun-Chao, Peng, Robert Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981486/
https://www.ncbi.nlm.nih.gov/pubmed/31935815
http://dx.doi.org/10.3390/ijms21010360
_version_ 1783491091839844352
author Chyau, Charng-Cherng
Wang, Hsueh-Fang
Zhang, Wen-Juan
Chen, Chin-Chu
Huang, Shiau-Huei
Chang, Chun-Chao
Peng, Robert Y.
author_facet Chyau, Charng-Cherng
Wang, Hsueh-Fang
Zhang, Wen-Juan
Chen, Chin-Chu
Huang, Shiau-Huei
Chang, Chun-Chao
Peng, Robert Y.
author_sort Chyau, Charng-Cherng
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) and -steatohepatitis (NASH) imply a state of excessive fat built-up in livers with/or without inflammation and have led to serious medical concerns in recent years. Antrodan (Ant), a purified β-glucan from A. cinnamomea has been shown to exhibit tremendous bioactivity, including hepatoprotective, antihyperlipidemic, antiliver cancer, and anti-inflammatory effects. Considering the already well-known alleviating bioactivity of A. cinnamomea for the alcoholic steatohepatitis (ASH), we propose that Ant can be beneficial to NAFLD, and that the AMPK/Sirt1/PPARγ/SREBP-1c pathways may be involved in such alleviations. To uncover this, we carried out this study with 60 male C57BL/6 mice fed high-fat high-fructose diet (HFD) for 60 days, in order to induce NAFLD/NASH. Mice were then grouped and treated (by oral administration) as: G1: control; G2: HFD (HFD control); G3: Ant, 40 mgkg (Ant control); G4: HFD+Orlistat (10 mg/kg) (as Orlistat control); G5: HFD+Ant L (20 mg/kg); and G6: HFD+Ant H (40 mg/kg) for 45 days. The results indicated Ant at 40 mg/kg effectively suppressed the plasma levels of malondialdehyde, total cholesterol, triglycerides, GOT, GPT, uric acid, glucose, and insulin; upregulated leptin, adiponectin, pAMPK, Sirt1, and down-regulated PPARγ and SREBP-1c. Conclusively, Ant effectively alleviates NAFLD via AMPK/Sirt1/CREBP-1c/PPARγ pathway.
format Online
Article
Text
id pubmed-6981486
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69814862020-02-07 Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway Chyau, Charng-Cherng Wang, Hsueh-Fang Zhang, Wen-Juan Chen, Chin-Chu Huang, Shiau-Huei Chang, Chun-Chao Peng, Robert Y. Int J Mol Sci Article Non-alcoholic fatty liver disease (NAFLD) and -steatohepatitis (NASH) imply a state of excessive fat built-up in livers with/or without inflammation and have led to serious medical concerns in recent years. Antrodan (Ant), a purified β-glucan from A. cinnamomea has been shown to exhibit tremendous bioactivity, including hepatoprotective, antihyperlipidemic, antiliver cancer, and anti-inflammatory effects. Considering the already well-known alleviating bioactivity of A. cinnamomea for the alcoholic steatohepatitis (ASH), we propose that Ant can be beneficial to NAFLD, and that the AMPK/Sirt1/PPARγ/SREBP-1c pathways may be involved in such alleviations. To uncover this, we carried out this study with 60 male C57BL/6 mice fed high-fat high-fructose diet (HFD) for 60 days, in order to induce NAFLD/NASH. Mice were then grouped and treated (by oral administration) as: G1: control; G2: HFD (HFD control); G3: Ant, 40 mgkg (Ant control); G4: HFD+Orlistat (10 mg/kg) (as Orlistat control); G5: HFD+Ant L (20 mg/kg); and G6: HFD+Ant H (40 mg/kg) for 45 days. The results indicated Ant at 40 mg/kg effectively suppressed the plasma levels of malondialdehyde, total cholesterol, triglycerides, GOT, GPT, uric acid, glucose, and insulin; upregulated leptin, adiponectin, pAMPK, Sirt1, and down-regulated PPARγ and SREBP-1c. Conclusively, Ant effectively alleviates NAFLD via AMPK/Sirt1/CREBP-1c/PPARγ pathway. MDPI 2020-01-06 /pmc/articles/PMC6981486/ /pubmed/31935815 http://dx.doi.org/10.3390/ijms21010360 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chyau, Charng-Cherng
Wang, Hsueh-Fang
Zhang, Wen-Juan
Chen, Chin-Chu
Huang, Shiau-Huei
Chang, Chun-Chao
Peng, Robert Y.
Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway
title Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway
title_full Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway
title_fullStr Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway
title_full_unstemmed Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway
title_short Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway
title_sort antrodan alleviates high-fat and high-fructose diet-induced fatty liver disease in c57bl/6 mice model via ampk/sirt1/srebp-1c/pparγ pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981486/
https://www.ncbi.nlm.nih.gov/pubmed/31935815
http://dx.doi.org/10.3390/ijms21010360
work_keys_str_mv AT chyaucharngcherng antrodanalleviateshighfatandhighfructosedietinducedfattyliverdiseaseinc57bl6micemodelviaampksirt1srebp1cppargpathway
AT wanghsuehfang antrodanalleviateshighfatandhighfructosedietinducedfattyliverdiseaseinc57bl6micemodelviaampksirt1srebp1cppargpathway
AT zhangwenjuan antrodanalleviateshighfatandhighfructosedietinducedfattyliverdiseaseinc57bl6micemodelviaampksirt1srebp1cppargpathway
AT chenchinchu antrodanalleviateshighfatandhighfructosedietinducedfattyliverdiseaseinc57bl6micemodelviaampksirt1srebp1cppargpathway
AT huangshiauhuei antrodanalleviateshighfatandhighfructosedietinducedfattyliverdiseaseinc57bl6micemodelviaampksirt1srebp1cppargpathway
AT changchunchao antrodanalleviateshighfatandhighfructosedietinducedfattyliverdiseaseinc57bl6micemodelviaampksirt1srebp1cppargpathway
AT pengroberty antrodanalleviateshighfatandhighfructosedietinducedfattyliverdiseaseinc57bl6micemodelviaampksirt1srebp1cppargpathway